The company reported positive Phase III trial results for its antibody-drug conjugate izalontamab brengitecan in treating advanced triple-negative breast cancer, showing significant improvements in survival versus chemotherapy. This marks the third successful pivotal study for this drug candidate. The stock recently closed at $62.37, showing strong recent performance with gains of 14.9% over 30 days and 16.7% year-to-date. The company maintains an attractive dividend yield of 4% and a strong dividend history, though it has lagged the broader Nasdaq over the past year.